Format

Send to

Choose Destination
World J Gastroenterol. 2014 Jul 21;20(27):8993-7. doi: 10.3748/wjg.v20.i27.8993.

De-escalating therapy in gastric aggressive lymphoma.

Author information

1
Rosanna Cuccurullo, Silvia Govi, Andrés JM Ferreri, Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy.

Abstract

The treatment of primary gastric diffuse large B-cell lymphoma (DLBCL) has changed radically over the last 10-15 years, with the abandonment of routine gastrectomy in favor of more conservative therapies. Low-level evidence suggests that consolidation radiotherapy could be avoided in patients with limited-stage DLBCL of the stomach who achieve complete remission after rituximab-CHOP combination. Small, recent prospective trials suggest that selected patients with limited-stage Helicobacter pylori (H. pylori)-positive DLBCL of the stomach and favorable prognostic factors can be managed with antibiotics alone, with excellent disease control and cure rates, keeping chemo-radiotherapy for unresponsive patients. This recommendation should equally regard patients with mucosa-associated lymphoid tissue-related or de novo DLBCL. Future studies should be focused on the establishment of reliable variables able to distinguish the best candidates for exclusive treatment with H. pylori eradication from those who need for conventional chemo-immunotherapy.

KEYWORDS:

Antibiotic therapy; Diffuse large B-cell lymphoma; Gastric lymphoma; Helicobacter pylori; Rituximab

PMID:
25083073
PMCID:
PMC4112900
DOI:
10.3748/wjg.v20.i27.8993
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center